Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07084571 2026-03-12

FORTITUDE

Recruiting

200 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02945579 2026-03-09

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

Phase NA Recruiting

120 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07457359 2026-03-09

NEOTRIO-2

Phase 2 Recruiting

18 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06318897 2026-03-04

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

Phase 2 Recruiting

28 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06709651 2026-03-04

MINA

Recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Phase 2 Recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07342283 2026-03-02

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Phase 2 Recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03808337 2026-02-27

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Phase 2 Recruiting

145 enrolled

BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Phase 2 Recruiting

110 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06802757 2026-02-25

PRISM-TNBC

Phase 2 Recruiting

72 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06976944 2026-02-23

PRELUDE

Phase 2 Recruiting

44 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04861077 2026-02-20

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

Phase EARLY_PHASE1 Recruiting

20 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04683679 2026-02-17

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

Phase 2 Recruiting

34 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06291064 2026-02-17

TARMAC

Phase 2 Recruiting

85 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06744465 2026-02-17

NearWave Optical Molecular Monitoring

Phase NA Recruiting

15 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

PREDICT-RD

FACT-TN

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

BELIEVE

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

JS207 Combination Therapy in Triple-negative Breast Cancer

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

EVOLVE-BDT

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

PAveMenT

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

ABBICAR

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer

Breast Cancer PSMA PET

BCTOP-T-M01

LESLIE

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

TRIPLEX

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Access to Genetic Testing in Underserved Patients With Cancer

CROWN

I-SPY

PNeoVCA

FORTITUDE

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

NEOTRIO-2

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

MINA

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

PRISM-TNBC

PRELUDE

Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

TARMAC

NearWave Optical Molecular Monitoring